Top

World Journal of Surgery

Published in:

01-05-2014

The Protective Effect of Parity in Hormone Receptor-Positive, Ki-67 Expressing Breast Cancer

Authors: Se Kyung Lee, Seok Won Kim, Sang-Ah Han, Won Ho Kil, Jeong Eon Lee, Seok Jin Nam

Published in: World Journal of Surgery | Issue 5/2014

Abstract

Background

Epidemiologic studies showed that the experience of pregnancy is associated with a reduced risk of breast cancer. We hypothesized that parity may differentially be associated with the development of invasive breast cancer by each subtype.

Methods

We reviewed the clinical, radiological, and pathological records of women diagnosed with invasive ductal carcinoma of the breast at Samsung Medical Center between 2005 and 2009. Clinicopathologic results were assessed by χ² and Fisher’s exact tests with a Bonferroni correction for categorical variables, and by the Kruskal–Wallis test for nonparametric continuous variables. A multinomial logistic regression model was used for multivariate analysis.

Results

Among a total of 3,095 patients, 283 (9.14 %) patients were nulliparous. Older age, higher pN, and expression of HER2 were associated with parity. In the analysis between parity and molecular subtypes, parity also had a variable influence on breast cancer subtypes (p = 0.032). Intergroup analysis with multiple comparison showed that luminal B subtype was related to nulliparity compared with HER2-positive subtypes (p = 0.03).

Conclusions

The effect of parity on the development of breast cancer differed by hormone receptor and HER2 expression. It seems that parity might have a protective effect against hormone receptor-positive breast cancer, especially cancers expressing HR+ and Ki-67. Further basic research to define and understand this result is ongoing.

Kelsey JL, Gammon MD, John EM (1993) Reproductive factors and breast cancer. Epidemiol Rev 15:36–47PubMed

Mustacchi P (1961) Ramazzini and Rigoni-Stern on parity and breast cancer. Clinical impression and statistical corroboration. Arch Intern Med 108:639–642PubMedCrossRef

MacMahon B, Cole P, Lin TM et al (1970) Age at first birth and breast cancer risk. Bull World Health Organ 43:209–221PubMedCentralPubMed

Lambe M, Hsieh C, Trichopoulos D et al (1994) Transient increase in the risk of breast cancer after giving birth. N Engl J Med 331:5–9. doi:10.1056/NEJM199407073310102 PubMedCrossRef

Peterson NB, Huang Y, Newcomb PA et al (2008) Childbearing recency and modifiers of premenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 17:3284–3287. doi:10.1158/1055-9965.EPI-08-0577 PubMedCentralPubMedCrossRef

Daling JR, Malone KE, Doody DR et al (2002) The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev 11:235–241PubMed

Bladstrom A, Anderson H, Olsson H (2003) Worse survival in breast cancer among women with recent childbirth: results from a Swedish population-based register study. Clin Breast Cancer 4:280–285PubMedCrossRef

Ma H, Bernstein L, Pike MC et al (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8:R43. doi:10.1186/bcr1525 PubMedCentralPubMedCrossRef

Ma H, Wang Y, Sullivan-Halley J et al (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences study. Cancer Res 70:575–587. doi:10.1158/0008-5472.CAN-09-3460 PubMedCentralPubMedCrossRef

10.

Lord SJ, Bernstein L, Johnson KA et al (2008) Breast cancer risk and hormone receptor status in older women by parity, age of first birth, and breastfeeding: a case–control study. Cancer Epidemiol Biomarkers Prev 17:1723–1730. doi:10.1158/1055-9965.EPI-07-2824 PubMedCentralPubMedCrossRef

11.

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093

12.

Voduc KD, Cheang MC, Tyldesley S et al (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691. doi:10.1200/JCO.2009.24.9284 PubMedCrossRef

13.

Allred DC, Harvey JM, Berardo M et al (1998) Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155–168PubMed

14.

Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747. doi:10.1093/annonc/mdr304 PubMedCentralPubMedCrossRef

15.

Huang HJ, Neven P, Drijkoningen M et al (2005) Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 91:81–87. doi:10.1007/s10549-004-8235-8 PubMedCrossRef

16.

Rosenberg LU, Einarsdottir K, Friman EI et al (2006) Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15:2482–2488. doi:10.1158/1055-9965.EPI-06-0489 PubMedCrossRef

17.

Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103:470–477. doi:10.1093/jnci/djr030 PubMedCentralPubMedCrossRef

18.

Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123–139. doi:10.1007/s10549-007-9632-6 PubMedCentralPubMedCrossRef

19.

Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439–443. doi:10.1158/1055-9965.EPI-06-0806 PubMedCrossRef

20.

Phipps AI, Malone KE, Porter PL et al (2008) Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer. Cancer 113:1521–1526. doi:10.1002/cncr.23786 PubMedCentralPubMedCrossRef

21.

Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20:1071–1082. doi:10.1007/s10552-009-9331-1 PubMedCrossRef

22.

Butt S, Borgquist S, Anagnostaki L et al (2009) Parity and age at first childbirth in relation to the risk of different breast cancer subgroups. Int J Cancer 125:1926–1934. doi:10.1002/ijc.24494 PubMedCrossRef

23.

Nichols HB, Trentham-Dietz A, Love RR et al (2005) Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev 14:41–47PubMedCrossRef

24.

Balsari A, Casalini P, Bufalino R et al (2003) Role of hormonal risk factors in HER2-positive breast carcinomas. Br J Cancer 88:1032–1034. doi:10.1038/sj.bjc.6600844 PubMedCentralPubMedCrossRef

25.

Reed W, Sandstad B, Holm R et al (2003) The prognostic impact of hormone receptors and c-erbB-2 in pregnancy-associated breast cancer and their correlation with BRCA1 and cell cycle modulators. Int J Surg Pathol 11:65–74PubMedCrossRef

26.

Treurniet HF, Rookus MA, Peterse HL et al (1992) Differences in breast cancer risk factors to neu (c-erbB-2) protein overexpression of the breast tumor. Cancer Res 52:2344–2345PubMed

27.

Chen T, Lukanova A, Grankvist K et al (2010) IGF-I during primiparous pregnancy and maternal risk of breast cancer. Breast Cancer Res Treat 121:169–175. doi:10.1007/s10549-009-0519-6 PubMedCentralPubMedCrossRef

28.

Wu S, Zhou B, Xu L et al (2010) Interaction between nuclear insulin receptor substrate-2 and NF-kappaB in IGF-1 induces response in breast cancer cells. Oncol Rep 24:1541–1550PubMedCrossRef

29.

Toniolo P, Grankvist K, Wulff M et al (2010) Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer. Cancer Res 70:6779–6786. doi:10.1158/0008-5472.CAN-09-4622 PubMedCentralPubMedCrossRef

30.

Russo IH, Russo J (2007) Primary prevention of breast cancer by hormone-induced differentiation. Recent Results Cancer Res 174:111–130PubMedCrossRef

31.

Jacobson HI, Lemanski N, Agarwal A et al (2010) A proposed unified mechanism for the reduction of human breast cancer risk by the hormones of pregnancy. Cancer Prev Res (Phila) 3:212–220. doi:10.1158/1940-6207.CAPR-09-0050 CrossRef

32.

Torres CG, Pino AM, Sierralta WD (2009) A cyclized peptide derived from alpha-fetoprotein inhibits the proliferation of ER-positive canine mammary cancer cells. Oncol Rep 21:1397–1404PubMed

33.

Vakharia D, Mizejewski GJ (2000) Human alpha-fetoprotein peptides bind estrogen receptor and estradiol, and suppress breast cancer. Breast Cancer Res Treat 63:41–52PubMedCrossRef

34.

Melbye M, Wohlfahrt J, Lei U et al (2000) Alpha-fetoprotein levels in maternal serum during pregnancy and maternal breast cancer incidence. J Natl Cancer Inst 92:1001–1005PubMedCrossRef

35.

Chen Y, Kibriya MG, Jasmine F et al (2008) Do placental genes affect maternal breast cancer? Association between offspring’s CGB5 and CSH1 gene variants and maternal breast cancer risk. Cancer Res 68:9729–9734. doi:10.1158/0008-5472.CAN-08-2243 PubMedCentralPubMedCrossRef

36.

Lojun S, Bao S, Lei ZM et al (1997) Presence of functional luteinizing hormone/chorionic gonadotropin (hCG) receptors in human breast cell lines: implications supporting the premise that hCG protects women against breast cancer. Biol Reprod 57:1202–1210PubMedCrossRef

37.

Meduri G, Charnaux N, Loosfelt H et al (1997) Luteinizing hormone/human chorionic gonadotropin receptors in breast cancer. Cancer Res 57:857–864PubMed

38.

Villacampa MJ, Moro R, Naval J et al (1984) Alpha-fetoprotein receptors in a human breast cancer cell line. Biochem Biophys Res Commun 122:1322–1327PubMedCrossRef

Title: The Protective Effect of Parity in Hormone Receptor-Positive, Ki-67 Expressing Breast Cancer
Authors: Se Kyung Lee
Seok Won Kim
Sang-Ah Han
Won Ho Kil
Jeong Eon Lee
Seok Jin Nam
Publication date: 01-05-2014
Publisher: Springer US
Published in: World Journal of Surgery / Issue 5/2014
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-014-2468-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Protective Effect of Parity in Hormone Receptor-Positive, Ki-67 Expressing Breast Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2014

The Hartford Consensus: How to Maximize Survivability in Active Shooter and Intentional Mass Casualty Events

Prognostic Value of CEA and CK20 mRNA in the Peritoneal Lavage Fluid of Patients Undergoing Curative Surgery for Gastric Cancer

Surgical Resection versus Conformal Radiotherapy Combined with TACE for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Comparative Study: Reply

Management of Thoracic Esophageal Perforation

Using Protamine Can Significantly Reduce the Incidence of Bleeding Complications after Carotid Endarterectomy without Increasing the Risk of Ischemic Cerebral Events

Morbidity of Chemotherapy Administration and Satisfaction in Breast Cancer Patients: A Comparative Study of Totally Implantable Venous Access Device (TIVAD) Versus Peripheral Venous Access Usage